CNTX-4975

Unassigned

New Medicines

Moderate-severe knee osteoarthritis pain

Information

New formulation
Centrexion Therapeutics
Centrexion Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Ultra-pure, synthetic form of trans-capsaicin
OA is one of the most common chronic diseases, with an estimated overall prevalence in the general adult population of 24% for knee OA [2].
Moderate-severe knee osteoarthritis pain
Intraarticular